【摘要】 目的:探讨急性心肌梗死患者采用瑞替普酶与尿激酶溶栓治疗的疗效差异。方法:研究将2015年5月～2017年5月收治的78例急性心肌梗死患者进行随机分组,采用尿激酶治疗的为参照组(39例),采用瑞替普酶治疗的为试验组(39例),对比两组患者的临床治疗效果。结果:两组患者的不良反应发生率对比差异不明显(P>0.05);试验组的胸痛缓解率、冠状动脉再通率、生存率明显高于参照组,组间的数据对比差异显著,有统计学意义(P<0.05)。结论:急性心肌梗死采用瑞替普酶治疗的冠脉再通率更高,更有利于缓解患者的胸痛症状,提升患者的生存率,且治疗安全,更适合用于临床应用。更多还原

【Abstract】 Objective:To investigate the difference of efficacy of reteplase and urokinase thrombolytic in the treatment of acute myocardial infarction.Methods:78 patients with acute myocardial infarction admitted from May 2015 to May 2017 were randomly divided into two groups,used urokinase treatment as reference group(39 cases),used reteplase therapy as experimental group(39 cases),clinical therapeutic effects were compared between the two groups.Results:There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05),chest pain remission rate,coronary recanalization rate,survival rate of experimental group was significantly higher than that of the control group,the comparison of data between groups was statistically significant(P<0.05).Conclusion:The coronary recurrence rate of using reteplase in treating with acute myocardial infarction was higher,which is more conducive to ease the chest pain symptoms,improve the survival rate of patients,and the treatment is safe,more suitable for clinical application.更多还原